Investors are still waiting for the other shoe to drop on a slowdown in deal flow

The fear has been that a slowdown in venture financing and partnering is inevitable, due to both restrictions in travel and the market implosion. But there are few signs of a slowdown yet, and it’s not yet clear when or if the lag will happen, or what it will look like.

In BioCentury’s survey of biopharma businesses from the first week of March, 62% of respondents said they were concerned about their company’s ability to raise money. Companies also reported canceling or postponing roadshows, investor meetings and partnering meetings (see “BioCentury Survey Finds Action Lags Concern About COVID-19’s Business Impact”)...